Skip to content

NeoGenomics NEO Additional Paid-In Capital

Additional Paid-In Capital at other companies

Labcorp Holdings logo
Labcorp HoldingsLH
$0-100%
Quest Diagnostics logo
Quest DiagnosticsDGX
$2.35B+1.6%
Guardant Health logo
Guardant HealthGH
$2.93B+18.5%
Natera, Inc. logo
Natera, Inc.NTRA
$4.64B+19.6%
Tempus AI, Inc. logo
Tempus AI, Inc.TEM
$2.95B+15.8%
Personalis, Inc. logo
Personalis, Inc.PSNL

Other financials

Income statement

See full
Revenue$186.7M+11.1%
Gross profit$80.9M+10.4%
Operating income-$18.2M+34.4%
Net income-$17.1M+34.0%
EPS (diluted)-$0.13+35.0%

Balance sheet

See full
Cash & equivalents$146.1M-57.8%
Total debt$66.3M+5.3%
Total equity$828.8M-6.7%
Total assets$1.3B-15.9%

Cash flow

See full
Operating cash flow-$8.1M+67.9%
CapEx$5.0M+11.1%
Free cash flow-$13.1M+56.0%

Valuation

See full
Market cap$1.68B-21.0%
Enterprise value$1.6B-5.6%
P/S2.3×-0.9×

Profitability

See full
Gross margin43.2%-1.1pp
Operating margin-14.2%+1.1pp
Net margin-13.3%+2.4pp
FCF margin-4.9%

Returns & leverage

See full
Return on equity-11.6%+6.2pp
Debt / equity0.1×0.0×
Current ratio4.4×+2.4×

Where this comes from

Reported directly by NeoGenomics in its filing.

Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.

The official record: NeoGenomics’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about NeoGenomics's additional paid-in capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is NeoGenomics's additional paid-in capital?
NeoGenomics (NEO) reported additional paid-in capital of $1.28B in Q1 2026.
How has NeoGenomics's additional paid-in capital changed year-over-year?
NeoGenomics's additional paid-in capital increased by 3.2% year-over-year, from $1.24B to $1.28B.
What is the long-term trend for NeoGenomics's additional paid-in capital?
Over 5 years (2020 to 2025), NeoGenomics's additional paid-in capital has grown at a 12.6% compound annual growth rate (CAGR), from $701.36M to $1.27B.
What does additional paid-in capital mean?
Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.